The AVP-receptor antagonists, conivaptan, lixivaptan, and tolvaptan, are being studied for the treatment of hyponatremia. Conivaptan has been shown in clinical trials to increase free-water ...
Am J Health Syst Pharm. 2007;64(3):253-265. Preparation and Dosing. As an i.v. agent, conivaptan is compatible with 5% dextrose and is stable for up to 24 hours after mixing. Conivaptan should not ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback